{"id":61168,"date":"2025-04-28T22:06:22","date_gmt":"2025-04-28T20:06:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fellow-health-to-present-innovative-research-on-prostate-cancer-biomarkers-and-pvsa-testing-at-aua-2025\/"},"modified":"2025-04-28T22:06:22","modified_gmt":"2025-04-28T20:06:22","slug":"fellow-health-to-present-innovative-research-on-prostate-cancer-biomarkers-and-pvsa-testing-at-aua-2025","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fellow-health-to-present-innovative-research-on-prostate-cancer-biomarkers-and-pvsa-testing-at-aua-2025\/","title":{"rendered":"Fellow Health to Present Innovative Research on Prostate Cancer Biomarkers and PVSA Testing at AUA 2025"},"content":{"rendered":"
\n

\nFirst multi-center clinical study of cell free RNA and DNA methylation biomarkers in seminal fluid shows promise for accurate, non-invasive detection of clinically significant prostate cancer.<\/i>\n<\/p>\n

SAN LEANDRO, Calif.–(BUSINESS WIRE)–Fellow Health<\/a>, a company focused on advancing male reproductive health through patient-centric testing solutions, today announced the presentation of four posters at the American Urological Association (AUA)<\/a> 2025 meeting, taking place April 26\u201329 in Las Vegas. The studies highlight mail-in semen analysis as a potential post-PSA reflex test as well as an alternative to in-clinic post-vasectomy semen analysis (PVSA).\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nIn a large multi-center study, researchers demonstrated that cell free RNA expression and DNA methylation biomarkers in seminal fluid can differentiate clinically significant prostate cancer (Grade Group 2+) from indolent cancer or no cancer. The RNA study identified a panel of transcripts that when combined with age and PSA resulted in an AUC of 0.827. Similarly, using a proprietary method for analyzing DNA methylation combined with AI, an AUC of 0.838 was obtained. Together, the findings point to a novel, non-invasive, mail-in test that could reduce unnecessary biopsies in men with elevated PSA.\n<\/p>\n

\n\u201cToo many men with elevated PSA undergo unnecessary prostate biopsies. In our study, even in the cohort that had undergone MRI prior to biopsy, almost 70% of men had either indolent cancer or no cancer,\u201d said Kim Clark-Langone, PhD, Senior Vice President of Research and Development at Fellow Health. \u201cThese studies show that seminal fluid holds untapped diagnostic power. We see mail-in semen analysis as a novel post-PSA reflex test that can prevent unnecessary biopsies.”\n<\/p>\n

\nThe second set of studies evaluated both the stability and real-world performance of mail-in PVSA. Researchers found that sperm samples remained stable over a 10-day period when stored in Fellow Health\u2019s proprietary preservative, and the retest rate was just 4.2% higher than with fresh samples. These findings validate Fellow Health\u2019s mail-in PVSA as a reliable, efficient alternative to in-clinic testing.\n<\/p>\n

\n\u201cEquity in men\u2019s reproductive health starts with meeting people where they are,\u201d said James F. Smith, MD, MS, Chief Medical Officer and NYS Laboratory Director at Fellow Health. \u201cMail-in PVSA testing removes barriers like geography, time, and stigma. This is about more than convenience\u2014it\u2019s about ensuring every man has access to high-quality care, no matter his circumstances.\u201d\n<\/p>\n

\nPresentation Details<\/b>\n<\/p>\n